Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID‐19: coincidence or underestimated risk factor?

Схожие документы

• Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS)
  по: Sturm, Lukas, et al.
  Опубликовано: (2018)
• Proton Pump Inhibitors and Cardiovascular Risk
  по: Ghebremariam, Yohannes T., et al.
  Опубликовано: (2014)
• Proton pump inhibitors and risk of dementia
  по: Wijarnpreecha, Karn, et al.
  Опубликовано: (2016)
• Cardiovascular Risk of Proton Pump Inhibitors
  по: Ariel, Hannah, et al.
  Опубликовано: (2019)
• HCV-Specific T Cell Responses During and After Chronic HCV Infection
  по: Luxenburger, Hendrik, et al.
  Опубликовано: (2018)